Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Livagen Dosing Protocol: 20 mg Vial — Liver Bioregulator & Hepatoprotection Guide

Livagen (Lys-Glu-Asp-Pro tetrapeptide) Russian liver bioregulator dosing guide — hepatocyte gene expression normalization for liver aging, detoxification, and hepatoprotection.

Quickstart highlights

Livagen (Lys-Glu-Asp-Pro, KEDP) is a tetrapeptide bioregulator from Khavinson's group targeting hepatic tissue.

  • Concentration: 2 mg/mL (20 mg + 10 mL bac water, in 2.5 mL portions).
  • At 2 mg/mL: 200 µg = 10 units daily x 10 days.
  • Livagen targets hepatocyte CYP450, glutathione S-transferase, and regeneration gene normalization.
  • One 20 mg vial = 100 doses; 10 complete 10-day courses.
  • Monitor ALT/AST before and after each course to track hepatoprotective effect.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2 (10-day course)20010Once daily (morning)200 µg — 10 units; one 20 mg vial provides 100 doses
Maintenance20010Every other day200 µg EOD — hepatoprotective maintenance

Reconstitution steps

  1. Reconstitute in 2.5 mL bac water portions (5 mg per batch); inject slowly down vial wall.
  2. Swirl gently until dissolved. Final concentration: 2 mg/mL.
  3. Label with date; refrigerate 2–8 °C. Use within 28 days.

Supplies needed

10_day-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Normalize hepatocyte gene expression for phase I/II detoxification enzymes, antioxidant defense, and liver regeneration through the Livagen tetrapeptide bioregulator 10-day intensive course.

Off-cycle: 4–6 months between courses.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • Morning injection — liver function peaks during the morning metabolic window.
  • Used in Russian clinical settings for NAFLD, post-hepatitis recovery, and statin-induced hepatotoxicity support.
  • Monitor liver enzymes before and after each 10-day course.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Liver function panel (ALT, AST, GGT, albumin, bilirubin) at baseline and 6 weeks post-course.
  • Track fibroscan-measured liver stiffness if available (annually).
  • Log alcohol use, medication changes, and diet quality weekly.
Log your cycle in the calculator →

How this works & references

Livagen (Lys-Glu-Asp-Pro, KEDP) is a tetrapeptide bioregulator from Khavinson's group targeting hepatic tissue. Proposed mechanisms: normalization of cytochrome P450 enzyme expression in aging hepatocytes; restoration of glutathione S-transferase and UGT expression for phase II conjugation; stimulation of hepatocyte proliferation genes (HGF, EGF receptor) for regeneration. Russian applications include NAFLD management, post-viral hepatitis support, alcohol-related liver disease, and prevention of drug-induced hepatotoxicity.

Sources

  • Source: Khavinson VK et al. — Organ-specific peptide bioregulators. Ann N Y Acad Sci. 2010;1207:66-75

Frequently asked questions

Can Livagen be used during statin therapy?
Statins are metabolized by hepatic CYP3A4 and can cause statin myopathy and elevated liver enzymes in susceptible individuals. Livagen's proposed normalization of CYP450 enzyme expression may support hepatocyte function during statin therapy, potentially reducing statin-related hepatotoxicity risk. No drug interaction data exists; use with physician guidance.
Is Livagen appropriate for alcoholic liver disease?
Russian practitioners apply Livagen in alcohol-related liver disease support during sobriety periods — targeting restoration of hepatocyte gene expression damaged by chronic alcohol exposure. It is not a treatment for active alcohol dependence. Use only in conjunction with complete alcohol abstinence and standard hepatology care.
How is Livagen different from milk thistle (silymarin) for liver support?
Silymarin inhibits hepatic lipid peroxidation and provides antioxidant protection via flavonoid activity. Livagen is proposed to act at the gene expression level, normalizing transcription of detoxification and regeneration genes. Both target liver health but through different molecular mechanisms — they may be complementary.
Can Livagen help with NAFLD (non-alcoholic fatty liver disease)?
Russian clinical protocols include Livagen for NAFLD management, targeting normalization of hepatocyte lipid metabolism gene expression (reduction of SREBP-1c, normalization of PPAR-alpha — similar to what lifestyle and metformin target). No published clinical trial specifically for NAFLD with Livagen exists.
Can Livagen be combined with glutathione injections?
Yes — glutathione provides immediate hepatic antioxidant support, while Livagen normalizes the hepatocyte's own glutathione synthesis gene expression over time. Sequential or concurrent use is rational: glutathione for acute support; Livagen for long-term self-sufficiency restoration of hepatocyte antioxidant capacity.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.